Evidence map›Paper›PMID 26844873›Full record

Trial reportClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2016

Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

Antonio Pisani, Massimo Sabbatini, Massimo Imbriaco, Eleonora Riccio, Nadia Rubis, Anna Prinster, Annalisa Perna, Raffaele Liuzzi, Letizia Spinelli, Michele Santangelo and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02119052 (Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease), which is not on this map. Cited by 33 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 6 pooled it
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02119052 phase2 / phase3completednot on this map

Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease

TypeinterventionalSponsorFederico II UniversityRan2009Enrolled35ConditionsAutosomal Dominant Polycystic Kidney DiseaseArmsocteotride, placebo
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 6 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Transplant Indications in Polycystic Liver and Kidney DiseaseThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Review
  10. Article
  11. Reporting ADPK Disease Phenotypes on Abdominal Scans.Kidney international reports · 2025
    Article
  12. Review
  13. Ciliary G-Protein Coupled Receptor Signaling in Polycystic Kidney Disease.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Antonio PisaniNephrology Unit, Department of Public Health, Federico II University, Naples, Italy.
Massimo SabbatiniNephrology Unit, Department of Public Health, Federico II University, Naples, Italy.
Massimo ImbriacoDepartment of Radiology, Federico II University, Naples, Italy.
Eleonora RiccioNephrology Unit, Department of Public Health, Federico II University, Naples, Italy.
Nadia RubisIRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Daccò", Bergamo, Italy.
Anna PrinsterInstitute of Biostructure and Bioimaging, National Research Council, Naples, Italy.
Annalisa PernaIRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Daccò", Bergamo, Italy.
Raffaele LiuzziInstitute of Biostructure and Bioimaging, National Research Council, Naples, Italy.
Letizia SpinelliDepartment of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
Michele SantangeloDepartment of Surgical Sciences and Nephrology, Federico II University, Naples, Italy.
Giuseppe RemuzziIRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Daccò", Bergamo, Italy; Nephrology and Dialysis Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Electronic address: Giuseppe.remuzzi@marionegri.it.
Piero RuggenentiIRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Daccò", Bergamo, Italy; Nephrology and Dialysis Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
ALADIN Study Group
Federico II University Hospital · ITMario Negri Institute for Pharmacological Research · ITUniversity of Milan · ITInstitute of Biostructure and Bioimaging · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsShort-term studies have shown that somatostatin analogues are effective in patients with polycystic kidney and liver disease. We evaluated the long-term effects of long-acting release octreotide (octreotide LAR), a somatostatin inhibitor, vs placebo in these patients.

methodsWe performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m(2) or more) at a single center in Italy. We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years. The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.

resultsBaseline characteristics were similar between groups. After 3 years, TLV decreased by 130.2 ± 133.2 mL in patients given octreotide LAR (7.8% ± 7.4%) (P = .003) but increased by 144.3 ± 316.8 mL (6.1% ± 14.1%) in patients given placebo. Change vs baseline differed significantly between groups (P = .004). Two years after treatment ended, TLV had decreased 14.4 ± 138.4 mL (0.8% ± 9.7%) from baseline in patients given octreotide LAR but increased by 224.4 ± 331.7 mL (11.0% ± 14.4%) in patients given placebo. Changes vs baseline still differed significantly between groups (P = .046). Decreases in TLV were similar in each sex; the change in TLV was greatest among subjects with larger baseline TLV. No patient withdrew because of side effects.

conclusionsIn a placebo-controlled study of patients with polycystic kidney and liver disease, 3 years of treatment with octreotide LAR significantly reduced liver volume; reductions were maintained for 2 years after treatment ended. Octreotide LAR was well-tolerated. ClinicalTrials.gov number: NCT02119052.

Indexed as

AdultCystsFemaleGastrointestinal AgentsHumansItalyLiverLiver DiseasesMagnetic Resonance ImagingMaleOctreotidePlacebosPolycystic Kidney, Autosomal DominantProspective StudiesSingle-Blind MethodTimeGastrointestinal AgentsOctreotidePlacebosADPKD VolumeCyst GrowthSomatostatin Analogue

Identifiers

PMID26844873
OpenAlexW2254093794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.